imatinib mesylate has been researched along with Cutaneous T-Cell Lymphoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, P; Behdad, A; Chen, Q; Guitart, J; Lu, X; Pro, B; Zhou, XA | 1 |
1 other study(ies) available for imatinib mesylate and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Cutaneous T-Cell Lymphoma, a Novel Manifestation of PDGFRA-Rearranged Neoplasm.
Topics: Antineoplastic Agents; Female; Gene Rearrangement; Humans; Imatinib Mesylate; Lymphoma, T-Cell, Cutaneous; Middle Aged; Receptor, Platelet-Derived Growth Factor alpha | 2018 |